Saturday, 21 March 2020

CBCT Dental Imaging Market To Observe Strong Development By 2019

Market Scenario:
Dental cone beam computed tomography (CT) is a special type of x-ray equipment used when regular dental or facial x-rays are not sufficient. The technology is used to produce three dimensional (3-D) images of the teeth, soft tissues, nerve pathways and bone in a single scan. The CBCT dental imaging industry is growing rapidly. The increasing use of 3D radiographic imaging in orthodontics and increasing adoption of CBCT imaging by dental professionals has boosted the revenue of this market.
The U.S., India & Europe market is expected to reach USD 565.3 million by the end of the forecast period due to rising CBCT Dental Imaging Market Trends and is expected to grow at a CAGR of 9.8%.
Key Finding
  • The U.S., India & Europe CBCT dental imaging market and is expected to reach USD 565.3 million by 2023.
  • Regionally, U.S. holds the largest CBCT dental imaging market share of U.S., India & Europe CBCT dental imaging market and is expected to reach USD 280.9 million by 2023.
  • India market is expected to be the fastest growing market, and expected to grow at a CAGR of 10.3% from 2016 to 2023
Key Players for U.S., India & Europe CBCT dental imaging market:
Some of the key players in this market are: Carestream Health (US), Dentsply Sirona (US), FONA Dental, S.R.O., Gendex, Imaging Sciences International, LLC (US), J.MORITA MFG.CORP. (Japan), KaVo Dental GmbH (Germany), NewTom, Planmeca OY, Prexion (US), Sinclair Dental/Dentaire (Canada), SOREDEX (Finland), Vatech Networks (Republic of Korea) and others.
Segments:
U.S., India & Europe CBCT dental imaging market has been segmented on the basis of type of detector which comprises of flat panel detectors, image intensifier. On the basis of application the market is segmented into dental implants, endodontics, orthodontics and others. On the basis of end users the market is segmented into hospitals & dental clinics, academic & research institutes and others.
Regional Analysis of U.S., India & Europe CBCT dental imaging market:
U.S. is the largest market for CBCT Dental Imaging market. The U.S. market for CBCT dental imaging is expected to grow at a CAGR of 9.5% and is expected to reach at USD 280.9 Million by the end of the forecast period.
Europe is the second-largest market for CBCT dental imaging which is expected to grow at a CAGR of 10.0%. India region is expected to be fastest growing region in CBCT dental imaging market.
The report for U.S., India & Europe CBCT Dental Imaging Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regionsTop of Form
Bottom of Form
Browse more Healthcare Reports @
https://www.marketresearchfuture.com/categories/healthcare-market-report
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Osteoporosis Drugs Market, Segments, Growth And Value Chain 2019



Market Scenario:
Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.
The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.
The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.
The market restraints are loss of patents of block busters, greater penetration of generics and fragmentation of market, poor efficacy and side effects of present therapies, non-life threatening nature and poor symptoms of osteoporosis etc.
Taking all the factors into consideration, we expect the global osteoporosis market which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.
Study Objectives Global Osteoporosis Drugs Market:
  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global osteoporosis drugs market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by drug class (bisphosphonates, calcitonins, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others), by route of administration (oral, injectable and others) and by gender (male, female and children).
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.
Key Players for Global Osteoporosis Drugs Market:
Some of the key players in this market are: Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others.
Segments:
Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.
Intended Audience:
  • Osteoporosis Drugs Manufacturers
  • Osteoporosis Drugs Suppliers
  • Private Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Government Research Laboratories
  • Contract Manufacturing Organizations
Regional Analysis of Global Osteoporosis Drugs Market:
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.
The report for Global Osteoporosis Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
Table Of Contents
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power Of Suppliers
4.1.2 Bargaining Power Of Customer
4.1.3 Intensity Of Competitor’s
4.1.4 Threat Of New Entrants
...TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Anti-Viral Drugs Market Growth And Restrain Factors Analysis By 2022



Global Anti-viral drugs Market Information, by application (hepatitis, HIV/AIDS, herpes, influenza and others) and by mechanism of action (nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others) - Forecast to 2022
Market Scenario:
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period.
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market.
Key Players
MRFR have enlisted some of the prominent companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and Astra Zeneca AB.
Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
Table Of Contents
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power Of Suppliers
4.1.2 Bargaining Power Of Customer
4.1.3 Intensity Of Competitor’s
4.1.4 Threat Of New Entrants
...TOC Continued!
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Friday, 20 March 2020

Meningococcal Vaccines Market Revenue, Opportunity, Forecast And Value Chain Analysis 2019

Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.
Market Synopsis
Meningococcal meningitis is a bacterial infection caused by Neisseria meningitides. Disease incidence is high in West and Central Africa, where historically, serogroup A has been the most important cause of disease. More recently, meningitis outbreaks have gradually been associated with serogroup C, and to a lesser extent, serogroup W.
The meningococcal vaccines market is complex and diverse, with regional variations in serogroup distribution with substantial use outside routine immunization. The vaccine has approximately 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y).
Market Influencer
Without an increase in production, the existing supply of conjugate MenACWY will be inadequate to meet the demand generated by the rising incidence of serogroups C and W, and the low availability of polysaccharide vaccines. Further, several multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the pipeline, and, if prequalified they will be registered for use in many geographies. Moreover, if they are made available at acceptable prices it could increase global demand in Meningococcal Vaccines Market Trends.
Market Drivers
  • Rise in prevalence of the meningococcal disease
    • According to a document published by the U.S. Department of Health & Human Services, in 2017, there were approximately 350 cases of meningococcal disease reported. The disease has an incidence rate of 0.11 cases per 100,000 people in the United States. Any population group can be affected by the disease, with maximum prevalence in children younger than one-year-old and a second peak in adolescence. Adolescents and young adults, ranging from 16 to 23 years old, have the highest rates of meningococcal disease.
    • Further, increasing incidence of meningococcal disease in West and Central Africa regions is expected to drive the demand in the African region
  • Booming mortality of the meningococcal disease is leading to increasing demand for the vaccines
    • Approximately 10 to 15 in 100 people affected with meningococcal disease will face mortality. Further, up to 1 in 5 survivors will have long-term disabilities, such as loss of limb, deafness, and damage to the nervous system brain among others
  • Escalating positive results with the vaccines to boost the demand in the market
  • Growing research and development activities by prominent players in the industry
Market Restraints
  • Withdrawn production of polysaccharide vaccines has resulted in reduced country access, particularly for MICs in various regions. For example, Sanofi Pasteur, manufacturer of Menomune, declared in 2017 that the company is discontinuing the production of the vaccine. With the production of Menomune at hold, there were no polysaccharide vaccines approved for use in the United States

Meningococcal Vaccines Market Segmentation

By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.
Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.
In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.
Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.
By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes
Hospitals and clinics control the global market for meningococcal vaccines. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.
Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.
By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.
UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.
Key Developments in the Global Meningococcal Vaccines Market
  • In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years
  • In 2018, GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age
  • In 2015, Novartis Bexsero vaccine was approved by the FDA for the prevention of meningitis B. This vaccine is used as active immunization to prevent invasive meningococcal disease caused by serogroup B
Key Players
  • Baxter international
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis Pharmaceuticals Inc.
  • JN-International Medical Corporation
  • Serum Institute of India Ltd.
  • GlaxoSmithKline
  • BIO-MED
  • Others
About Us
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Cell Counting Market 2019 Analysis, Opportunities And Forecast To 2023

Cell Counting Market is expected to cross USD 12.57 Billion by 2025 at a CAGR of 5.8%.
Market Synopsis
Cell counting is one of the methods for counting cells in life sciences, including medical diagnosis and treatment. The companies operating in this market acquire both organic and inorganic growth strategies to maintain and develop their positions in the market. The increasing funding for stem cell-based research supports the growth of the market.
Market Influencer
Increasing public-private investments and funding in stem cell-based research impact the growth of the cell counting industry positively.
Market Drivers
  • The increasing use of stem cells in various therapeutics is promoting government and private institutes to raise the funding for more development in this area. For instance, in March 2019, the governing Board of the California Institute for Regenerative Medicine (CIRM) funded USD 3.9 million to Ankasa Regenerative Therapeutics to develop the treatment for spinal degeneration which can cause chronic, progressive back pain.
  • The growth of the market is driven by the increasing number of product launches in the global cell counting market. Recently, in January 2019 the DeNovix Inc. launched CellDrop Cell Counting without Slides.
  • Increased R&D expenditure in the healthcare industry will support the growth of the cell counting market.
  • Increasing number of stem cell organizations globally support the growth of the market.
  • Rising incidence & prevalence of cancer will support the growth of the market.
Market Restraints
  • The high cost of devices and product recalls are likely to hamper the growth of the cell counting market during the forecast period. Recently in May 2019, Beckman Coulter Inc. recalled DxH800 and DxH600 and DxH 900 hematology analyzers due to risk of inaccurate results.
Cell Counting Market Segmentation
By Product
  • Consumables: The consumables segment includes reagents, assay kits, microplates, and others. The instruments are further segmented into reagents, assay kits, microplates, and others. This segment holds the largest share in the cell counting market due to repeating purchase of consumable products.
  • Instruments: Instruments are used in cell counting methods. The instruments are further segmented into spectrophotometers, flow cytometers, hematology analyzers, and cell counters. Increasing number of product launches will support the growth of the market. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.
By Application
  • Research Application: Cell counting is used for research applications for discovering new medicines. Cell counting has the main application in stem cell research to develop advanced therapy for various diseases. This segment holds the largest share in the cell counting market.
  • Clinical & Diagnostic Applications: Cell counting has a significant role in clinical and diagnosis applications. It is used for diagnosis of various kinds of blood disorders, including infection, anemia, and leukemia.
  • Others: Others include industrial and other commercial applications.
By End-User
  • Pharmaceutical & Biotechnology Companies: The largest segment, pharmaceutical, and biotechnology companies, primarily use cell counting for research purposes. In 2018, the pharmaceutical and biotechnology companies segment held the largest share of the market.
  • Hospitals: Hospitals used cell counting products for the diagnosis of various kinds of diseases such as blood disorders and malaria, among others.
  • Research Institutes: These re involved in specific research activities to develop new and advance treatment for various diseases. Stem cell research institutes are major consumers for cell counting products.
  • Others: These include academic institutes, among others.
By Region
  • Americas: The Americas dominates the global cell counting market owing to an increase in the incidence of cancer, the presence of well-established pharmaceutical and biotechnology industry, availability of technologically advanced products, and significant support from the government in the form of funds and grants.
  • Europe: The key factors driving the market growth are the growing research and development funding and support by government bodies for the healthcare sector, the presence of major manufacturers, and growing healthcare expenditure, among others.
  • Asia-Pacific: Asia-Pacific is the fastest-growing region for the cell counting market. This is due to developing healthcare infrastructure and rising drug development researchers.
  • Middle East & Africa: It is projected to account for the least share of the global market due to low per capita disposable incomes in the region and limited development of healthcare facilities.
Key Players
  • Thermo Fisher Scientific (US)
  • Merck KGaA (Germany)
  • Danaher Corporation (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Logos Biosystems, Inc. (South Korea)
  • Olympus Corporation (Japan)
  • Agilent Technologies, Inc. (US)
  • PerkinElmer, Inc. (US)
  • Sysmex Corporation (Japan)
  • Abbott Laboratories (US)
About Us
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Thalassemia Treatment Market Volume Forecast And Value Chain Analysis 2019

Market Forecast
Thalassemia Treatment Market Size is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.
Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.
Market Synopsis
Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.
Market Influencers
Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.
Market Drivers
  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.
  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.
  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.
  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.
Market Restraints
  • Stringent regulatory policies
  • High treatment costs
Segmentation
By Type
  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.
  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.
By Treatment
  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.
  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.
  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.
  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.
  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.
By End-User
  • Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.
  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.
  • Others: This segment includes research laboratories, educational institutes, among others.
By Region
  • Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.
  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.
  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.
  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.
Key Players
  • Novartis AG (Switzerland)
  • Bluebird Bio, Inc. (US)
  • Kiadis Pharma (Netherlands)
  • CELGENE CORPORATION (US)
  • Sangamo Therapeutics (US)
  • Acceleron Pharma, Inc. (US)
  • Gamida Cell (Israel)
About Us
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)